Maven Securities LTD Has $695,000 Stake in Guardian Pharmacy Services, Inc. $GRDN

Key Points

• Maven Securities LTD significantly reduced its holdings in Guardian Pharmacy Services, Inc. by 70.2%, owning 32,684 shares after selling 77,039 shares during the first quarter.
• Several investment firms, including JPMorgan Chase & Co. and BNP Paribas Financial Markets, have recently acquired new positions in the company, reflecting growing interest among major investors.
• Analysts have set a price target of $28.00 for Guardian Pharmacy Services, with a consensus rating of "Buy," indicating positive outlook from multiple research firms.

Maven Securities LTD trimmed its position in Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) by 70.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,684 shares of the company's stock after selling 77,039 shares during the period. Maven Securities LTD owned approximately 0.05% of Guardian Pharmacy Services worth $695,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of GRDN. LPL Financial LLC lifted its holdings in shares of Guardian Pharmacy Services by 4.8% in the fourth quarter. LPL Financial LLC now owns 17,679 shares of the company's stock valued at $358,000 after purchasing an additional 807 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in Guardian Pharmacy Services during the fourth quarter worth about $77,000. Geode Capital Management LLC bought a new stake in Guardian Pharmacy Services during the fourth quarter worth about $4,073,000. Wells Fargo & Company MN raised its holdings in Guardian Pharmacy Services by 353.7% during the fourth quarter. Wells Fargo & Company MN now owns 6,715 shares of the company's stock worth $136,000 after acquiring an additional 5,235 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in Guardian Pharmacy Services by 4.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 12,010 shares of the company's stock worth $243,000 after acquiring an additional 564 shares in the last quarter.

Insider Buying and Selling

In other news, Director John Ackerman sold 1,084,276 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $20.16, for a total value of $21,859,004.16. Following the transaction, the director owned 200,099 shares of the company's stock, valued at approximately $4,033,995.84. This represents a 84.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William E. Bindley sold 3,508,905 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $20.16, for a total value of $70,739,524.80. Following the completion of the transaction, the director directly owned 2,591,271 shares in the company, valued at $52,240,023.36. The trade was a 57.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,344,912 shares of company stock valued at $228,713,426 in the last ninety days. 63.71% of the stock is currently owned by company insiders.

Guardian Pharmacy Services Trading Down 1.7%

NYSE:GRDN traded down $0.46 on Friday, hitting $25.83. The company's stock had a trading volume of 417,788 shares, compared to its average volume of 206,149. The stock has a fifty day moving average of $21.28 and a two-hundred day moving average of $21.61. The firm has a market capitalization of $1.64 billion and a P/E ratio of -16.99. Guardian Pharmacy Services, Inc. has a one year low of $14.16 and a one year high of $26.91.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GRDN. Raymond James Financial set a $28.00 target price on Guardian Pharmacy Services and gave the stock an "outperform" rating in a report on Wednesday, May 14th. Truist Financial reiterated a "buy" rating and set a $28.00 target price (up previously from $25.00) on shares of Guardian Pharmacy Services in a report on Monday, May 19th. Finally, Wall Street Zen upgraded Guardian Pharmacy Services from a "hold" rating to a "strong-buy" rating in a report on Sunday, August 17th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Guardian Pharmacy Services currently has a consensus rating of "Buy" and an average price target of $25.67.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.